• Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025

• The Nashville Tennessee-based company is expected to report a 180.8% increase in revenue to $292 thousand from $104 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 23 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $4.25, about 39.8% above its last closing price of $2.56

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated August 4 at 11:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)